Clinical reference Biomarker Directory
Back to directory

B2M

Established

B2M is a cell-surface protein used as a key prognostic marker in multiple myeloma staging.

Also known as Beta-2-microglobulin β2M
In plain language

B2M is a small protein shed by cells throughout the body; high levels often mean a higher amount of cancer cells present, especially in multiple myeloma, where it's part of the standard staging system doctors use to plan treatment.

Biomarker & context

Beta-2 microglobulin (B2M) is a small protein present on the surface of nearly all nucleated cells, released into circulation in proportion to cell turnover. It is a core prognostic marker in multiple myeloma and certain lymphomas.

What it indicates

Elevated B2M reflects higher tumor burden and is incorporated into the International Staging System (ISS) for multiple myeloma alongside albumin; it is also elevated in various benign conditions (kidney dysfunction, inflammation, viral infection).

Diagnosis & clinical testing

Measured via serum immunoassay; a value <4 μg/mL is considered a favorable prognostic factor in myeloma, with one study showing median survival of 43 months (low B2M) versus 12 months (high B2M) in older cohorts. It is also a predictor of progression risk in asymptomatic (smoldering) myeloma.

Guiding treatment

B2M contributes directly to ISS staging, which guides risk stratification and treatment intensity decisions in multiple myeloma; newer research is examining the rate of B2M decline after treatment initiation as an added prognostic signal.

Clinical significance

Core component of the International Staging System (ISS) for multiple myeloma.

References
  1. Bataille, R., et al. Beta-2-microglobulin in myeloma: optimal use for staging, prognosis, and treatment. PubMed.
  2. Xu, et al. (2024). Prognostic significance of β2-microglobulin decline index in multiple myeloma. Frontiers in Oncology.